Effect of Gefitinib on Tumor Markers and Circulating Blood miR in Patients with Advanced Non-small Cell Lung Cancer with EGFR Mutation
Objective:To investigate the the effects of Gefitinib on tumor markers and circulating blood microRNA (miR) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation. Method:A total of 80 patients with advanced non-small cell lung cancer with EGFR mutation admitted to 910th Hospital of Joint Logistics Support Force from December 2021 to October 2023 were divided into control group (n=40) and observation group (n=40) according to random number table method. The control group was treated with Docetaxel,and the observation group was treated with Gefitinib. The total remission rate of treatment,incidence of various toxic and side effects,disease-related blood indexes[human epidermal growth factor receptor 2 (HER2),EGFR],tumor markers[carcinoembryonic antigen (CEA),neuron specific enolase (NSE) and cytokeratin 19 fragment (Cyfra21-1)]and circulating blood miR indexes (miR-155,miR-21 and miR-34a) before and after treatment were compared between the two groups. Result:The total remission rate of treatment in the observation group was significantly higher than that in the control group,and the incidence of various toxic and side effects were significantly lower than those in the control group,the differences were statistically significant (P<0.05). There were no significant differences in disease-related blood indexes,tumor markers and circulating blood miR indexes between the two groups before treatment (P>0.05). After treatment,disease-related blood indexes,tumor markers and circulating blood miR indexes in the observation group were significantly lower than those in the control group,the differences were statistically significant (P<0.05). Conclusion:The application of Gefitinib in patients with advanced non-small cell lung cancer with EGFR mutation has good effect and high safety,and can significantly improve the expression of tumor markers and circulating blood miR.
GefitinibEGFR mutationAdvanced non-small cell lung cancerTumor markersCirculating blood miR
万方数据
维普
